Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-07
2006-02-07
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212070, C514S221000, C514S222200, C514S243000, C514S249000, C514S299000, C514S359000, C514S367000, C514S375000, C514S307000, C514S312000, C514S314000, C514S230500, C514S248000, C514S213010, C514S259500, C514S394000, C514S301000, C514S302000, C544S353000, C544S354000, C544S050000, C544S051000, C544S105000, C544S235000, C544S284000, C540S567000, C540S593000, C540S468000, C540S569000, C548S305100, C548S305400
Reexamination Certificate
active
06995154
ABSTRACT:
The invention provides compounds of formula I:wherein R1to R5have any of the values defined in the specification, as well as pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, compositions, or salts to treat cancer. In embodiments, R4and R5taken together can be a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo; wherein each X is independently absent or is H, O, (C1–C4)alkyl, phenyl or benzyl; and wherein at least one of the chain members is an N—H group.
REFERENCES:
patent: 26065 (1859-11-01), Marvel et al.
patent: 2985661 (1961-05-01), Hien et al.
patent: 3449330 (1969-06-01), Guglielmetti et al.
patent: 3538097 (1970-11-01), Lowe et al.
patent: 5106863 (1992-04-01), Hajos et al.
patent: 5112532 (1992-05-01), Ninomiya et al.
patent: 5767142 (1998-06-01), La Voie et al.
patent: 5770617 (1998-06-01), LaVoie et al.
patent: 5807874 (1998-09-01), LaVoie et al.
patent: 1530628 (1989-12-01), None
patent: WO-96/36612 (1996-11-01), None
patent: WO-98/31673 (1998-07-01), None
Carter, Stephen K., M.D. et al.; Chemotherapy of Cancer, Second Edition, (1981); A Wiley & Sons, New York, New York; pp 362-365.
Dancey et al. “Current perspectives on camptothecins in cancer treatment” 1996, British Journal of Cancer, 74, 327-38.
Rangarajan et al. “2″-substituted 5-Phenylterbenzimidazoles as Topoisomerase I Poisons” 2000, Bioorganic & Medicinal Chemistry, 8, 1371-82.
Loewe et al. “Basic substituted 2,6-bisbenzimidazole derivatives, a novel series of substances with chemotherapeutic activity” 1974, Arzneimittel-Forschchung, 24(12), 1927-33.
International PCT Search Report for PCT/US 98/01005, (Jun. 22, 1998),5 pgs.
Bathini, Yadagiri, et al., “Convenient Routes to Substituted Benzimidazoles and Imidazolo[4,5-b]pyridines Using Nitrobenzene as Oxidant”,Synthetic Communications, 20(7), (1990),pp. 955-963.
Chen, Allan Y., et al., “A New Mammalian DNA Topoismerase I Poison Hoechst 33342: Cytoxicity and Drug Resistance in Human Cell Cultures”,Cancer Research, 53(6), (Mar. 15, 1993),pp. 1332-1337.
Chen, Allan Y., et al., “DNA Minor Groove-Binding Ligands: A Different Class of Mammalian DNA Topoisomerase I Inhibitors”,Proc. Natl. Acad. Sci., USA, 90, (Sep. 1993),pp. 8131-8135.
Chen, Allan Y., et al., “DNA Topoisomerases: Essential Enzymes and Lethal Targets”,Annu. Rev. Pharmacol. Toxicol., 34, (1994),pp. 191-218.
Goldman, Gustavo H., et al., “Differential poisoning of humand and aspergilus nidulans DNA topoisomerase I by Bi- and Terbenzimidazoles”,Biochemistry, 36(21), (1997), pp. 6488-6494.
Kim, J.S., et al., “Influence of steric factors on topoismerase I inhibition and cytotoxicity of bisbenzimidazoles related to Hoechst 33342”,Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, 36, Abstract No. 2689, Toronto, Ontario, Canada,(Mar. 1995), p. 451.
Kim, J. S., et al., “Influence of steric factors on topoisomerase I inhibition and cytotoxicity of bisbenzimidazoles related to Hoechst 33342”,Abstract 7—Proceedings of the 3rd Annual Scientific Retreat of the Cancer Institute of New Jersey, Princeton Marrtott Forrestal Village,(1995),p. 28.
Kim, Jung S., et al., “Quantitative structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents”,Bioorg. Med. Chem., 6(2), (1998),pp. 163-172.
Kim, J. S., et al., “Steric factors associated with the topoisomerase I inhibition and cytotoxicity of substituted bisbenzimidazoles”,Abstract 10-Proceedings of the American Association of Pharmaceutical Scientists Eastern Regional Meeting, (1995),p. 27.
Kim, Jung S., et al., “Structure-activity Relationships of Benzimidazoles and Related Heterocycles as Topoisomerase I Poisons”,Bioorganic&Med. Chem., 4, (1996),pp. 621-630.
Kim, Jung S., et al., “Substituted 2,5′-Bi-1H-benzimidazoles: Topoisomerase I Inhibition and Cytotoxicity”,J. Med. Chem., 39, (1996),pp. 992-998.
Kim, Jung S., et al., “Terbenzimidazoles: influence of 2″-, 4-, and 5- substituents on cytotoxicity and relative potency as topoisomerase I poisons”,J. Med. Chem., 40, (1997),pp. 2818-2824.
LaVoie, E. J. et al., “Structure-activity studies related to minor groove-binding ligands which inhibit mammalian DNA topoisomerase I”,Abstract 1—Proceedings of the 85th Annual Meeting of American Association for Cancer Research, San Francisco, CA,(Apr. 1994),p. 2699.
Loewe, H., et al., “Basic substituted 2, 6-bisbenzimidazole derivatives, a novel series of substances with chemotherapeutic activity”,Chemical Abstracts, 82(17), Abstract No. 112032,(Apr. 28, 1975),1 p.
Pilch, Daniel S., et al., “A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning”,Proc. Nat'l. Acad. Sci., USA, 94, (Dec. 1997),pp. 13565-13570.
Pilch, Daniel S., et al., “Biophysical Characterization of a Cytotoxic, Topoisomerase I Poison”,Abstract 8—Proceedings of the 3rd Annual Scientific Retreat of the Cancer Institute of New Jersey, Princeton Marriott Forrestal Village, Princeton, NJ,(Jun. 1, 1995),p. 3.
Pilch, Daniel S., et al., “Characterizing the DNA binding modes of a topoisomerase I-poisoning terbenzimidazole: evidence for both intercalative and minor groove binding properties”,Drug Design and Discovery, 13, (1996),pp. 115-133.
Porai-Koshits, B.A., et al., “Imidazole derivatives. Synthesis of some polybenzimidazoles”,Zhur. Obshchei Khim, 23, As related in Chemical Abstracts, 48 (1954) Col. 4523,(1953),pp. 835-841.
Singh, Malvinder P., et al., “Synthesis and Sequence-Specific DNA Binding of a Topoisomerase Inhibitory Analog of Hoechst 33258 Designed for Altered Base and Sequence Recognition”,Chem. Res. Toxicol., 5, (1992),pp. 597-607.
Sun, et al.,Chemical Abstracts, 123(15), Abstract No. 198740r, (1995), 1 p.
Sun, Qun, et al., “Structure activity of novel topoisomerase I inhibitors related to Hoechst 33342”,Abstract 6—Proceedings of the American Association of Pharmaceutical Scientists Eastern Regional Meeting, Hyatt Regency Hotel, New Brunswick, NJ,(Jun. 5-6, 1995),p. 25.
Sun, Qun, et al., “Structure Activity of Topoisomerase I Poisons related to Hoechst 33342”,Bioorganic&Medicinal Chemistry Letters, vol. 4, No. 24 vol. 4, No. 24,(1994),pp. 2871-2876.
Sun, Qun, et al., “Structure-activity studies related to minor groove-binding ligands which inhibit mammalian DNA topoisomerase I”,Cancer Institute of New Jersey's First Annual Scientific Retreat, Abstract 2, Princeton Marriott Forrestal Village, Princeton, NJ,(Jun. 7, 1994),p. 66.
Sun, Sun, et al., “Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors”,J. Med. Chem, 38, (1995),pp. 3638-3644.
Sun, Qun, et al., “Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors”,Chemical Abstracts, 123(15), Abstract No. 198740r,(1995),p. 1241.
Sun, Q., et al., “Synthesis and Pharmacological Evaluation of a Series of Novel DNA Topoisomerase I Inhibitors as Antitumor Agents”,Scientific Proceedings of 86th Annual Meeting of the American Association for Cancer Research, Abstract 3, Toronto, Canada, (Mar. 18-22, 1995),1 p.
Sun, Qun, et al., “Synthesis and pharmacological evaluation of a series of novel DNA topoisomerase I inhibitors as antitumor agents”,Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada,(1995),p. 2688.
Sun, Qun, et al., “Synthesis and pharmacological
Kim Jung Sun
LaVoie Edmond J.
Liu Leroy Fong
Mitchell Gregory W.
Padmanabhan Sreeni
Rutgers The State University of New Jersey
Viksnins Harris & Podys PLLP
LandOfFree
Heterocyclic topoisomerase poisons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic topoisomerase poisons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic topoisomerase poisons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681454